A systematic review of antiepileptic drug initiation and withdrawal

Neurologist

Volumn 15, Issue 3, 2009, Pages 122-131

  Shih, Jerry J ^a   Ochoa, Juan G ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antiepileptic drug; Initiation; Recurrence; Relapse; Seizure; Withdrawal

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREGABALIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ACADEMIC ACHIEVEMENT; ALGORITHM; ALOPECIA; ANTICONVULSANT THERAPY; APHASIA; APLASTIC ANEMIA; ATAXIA; BONE FRAGILITY; CHILDHOOD DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DECISION MAKING; DIPLOPIA; DISABILITY; DISEASE SEVERITY; DIZZINESS; DRIVING ABILITY; DROWSINESS; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; EPILEPSY; FATIGUE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; IRRITABILITY; LIFESTYLE; LIVER TOXICITY; NEPHROLITHIASIS; NEUROLOGIC EXAMINATION; OUTCOME ASSESSMENT; PARANOIA; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECURRENCE RISK; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; SKIN ALLERGY; SOCIAL PSYCHOLOGY; SOMNOLENCE; SUICIDAL IDEATION; SYSTEMATIC REVIEW; TERATOGENICITY; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; EPILEPSY; HUMANS; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE;

EID: 67649803414     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e3181901ad3     Document Type: Review

References (59)

1. Hauser WA, Rich SS, Lee JR, et al. Risk of recurrent seizures after two unprovoked seizures. N Engl J Med. 1998;338:429-434.
2. First Seizure Trial Group (FIR.S.T. Group). Randomized clinical trial of the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. Neurology. 1993;43:478-483.
3. Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomized controlled trial. Lancet. 2005;365:2007-2013.
4. Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology. 1991;41:965-972.
5. Hauser WA, Rich SS, Annegers JF, et al. Seizure recurrence after a 1st unprovoked seizure: an extended follow-up. Neurology. 1990;40:1163-1170.
6. van Donselaar C, Schimsheimer R, Geerts A, et al. Value of the electroencephalogram in adult patients with untreated idiopathic first seizures. Arch Neurol. 1992;49:231-237.
7. Schreiner A, Pohlmann-Eden B. Value of the early electroencephalogram after a first unprovoked seizure. Clin Electroencephalogr. 2003;34:140-144.
8. Kim LG, Johnson TL, Marson AG, et al. MRC MESS Study Group. Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurol. 2006;5:317-322.
9. Ramos Lizana J, Cassinello Garcia E, Carrasco Marina LL, et al. Seizure recurrence after a first unprovoked seizure in childhood: a prospective study. Epilepsia. 2000;41:1005-1013.
10. Kho LK, Lawn ND, Dunne JW, et al. First seizure presentation: do multiple seizures within 24 hours predict recurrence? Neurology. 2006;67:1047-1049.
11. Mussico M, Beghi E, Solari A, et al. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. Neurology. 1997;49:991-998.
12. Berg AT. Risk of recurrence after a first unprovoked seizure. Epilepsia. 2008;49:13-18.
13. Chadwick DW. The treatment of the first seizure: the benefits. Epilepsia. 2008;49:26-28.
14. Fritsch PO, Sidoroff A. Drug-induced Stevens Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol. 2000;1:349-360.
15. Mockenhaupt M, Messenheimer J, Tennis P, et al. Risk of Stevens Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64:1134-1138.
16. Perucca E. The treatment of the first seizure: the risks. Epilepsia. 2008;49: 29-34.
17. Arroyo S, De La Morena A. Life-threatening adverse events of antiepileptic drugs. Epilepsy Res. 2001;47:155-174.
18. United States Food and Drug Administration MedWatch on Antiepileptic Drugs. [FDA MedWatch Web site]. January 31, 2008. Available at: http:// www.fda.gov/medwatch/safety/2008/safety08.htm#Antiepileptic. Accessed February 2, 2008.
19. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia. 2001;42:1255-1260.
20. Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurology. 2005;4:781-786.
21. Meador KJ, Baker G, Cohen MJ, et al. Cognitive/behavioral teratogenetic effects of antiepileptic drugs. Epilepsy Behav. 2007;11:292-302.
22. Sheth RD, Gidal BE, Hermann BP. Pathological fractures in epilepsy. Epilepsy Behav. 2006;9:601-605.
23. Pack A. Bone health in people with epilepsy: Is it impaired and what are the risk factors? Seizure. 2008;17:181-186.
24. Perucca E, Meador KJ. Adverse effects of antiepileptic drugs. Acta Neurol Scand. 2005;112(suppl 181):31-35.
25. Gilliam F. Optimizing health outcomes in active epilepsy. Neurology. 2002; 58:9-20.
26. Shinnar S, Berg AT, Moshe SL, et al. The risk of seizure recurrence after a first unprovoked afebrile seizure in childhood: an extended follow-up. Pediatrics. 1996;98(2 Pt 1):216-225.
27. Hesdorffer DC, Logroscino G, Cascino G, et al. Recurrence of afebrile status epilepticus in a population-based study in Rochester, Minnesota. Neurology. 2007;69:73-78.
28. Stroink H, Brouwer OF, Arts WF, et al. The first unprovoked, untreated seizure in childhood: a hospital based study of the accuracy of the diagnosis, rate of recurrence, and long term outcome after recurrence. Dutch study of epilepsy in childhood. J Neurol Neurosurg Psychiatry. 1998;64:595-600.
29. Lawn ND, Bamlet WR, Radhakrishnan K, et al. Injuries due to seizures in persons with epilepsy: a population-based study. Neurology. 2004;63:1565-1570.
30. Wirrell EC. Long-term psychosocial outcome in typical absence epilepsy. Sometimes a wolf in sheeps' clothing. Arch Pediatr Adolesc Med. 1997;151: 152-158.
31. Wirrell EC. Epilepsy-related injuries. Epilepsia. 2006;47(suppl 1):79 - 86.
32. Carlton-Ford S, Miller R, Nealeigh N, et al. The effects of perceived stigma and psychological over-control on the behavioral problems of children with epilepsy. Seizure. 1997;6:383-391.
33. Leone MA, Solari A, Beghi E; FIRST Group. Treatment of the first tonic-clonic seizure does not affect long-term remission of epilepsy. Neurology. 2006;12:2227-2229.
34. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314-319.
35. Medical Research Council Antiepileptic Drug Withdrawal Group. Randomized study of antiepileptic drug withdrawal in patients in remission. Lancet 1991;337:1175-1180.
36. Specchio LM, Tramacere L, Neve AL, et al. Discontinuing antiepileptic drugs in patients who are seizure free on monotherapy. J Neurol Neurosurg Psychiatry. 2002;72:22-25.
37. Aktekin B, Dogan EA, Oguz Y, et al. Withdrawal of antiepileptic drugs in adult patients free of seizures for 4 years: a prospective study. Epilepsy Beh. 2006;8:616-619.
38. Berg A, Shinnar S. Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology. 1994;44:601-608.
39. Cardoso TAM. Hippocampal abnormalities and seizure recurrence after antiepileptic drug withdrawal. Neurology. 2006;67:134 -136.
40. Specchio LM, Beghi E. Should antiepileptic drugs be withdrawn in seizure-free patients? CNS Drugs. 2004;4:201-212.
41. Jacoby A. Psychosocial outcomes of antiepileptic drug discontinuation. Epi-lepsia. 1992;33:1123-1131.
42. Meador KJ. Cognitive and memory effects of the new antiepileptic drugs. Epilepsy Res. 2006;68:63-67.
43. Hessen E. Influence of major antiepileptic drugs on neuro-psychological function: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients on monotherapy. J Intl Neuro-psych Soc. 2007;13:393-400.
44. Hessen E, Lossius MI, Reinvang I, et al. Slight improvement in mood and irritability after antiepileptic drug withdrawal: a controlled study in patients on monotherapy. Epilepsy Beh. 2007;10:449-455.
45. Verrotti A, Trotta D, Salladini C, et al. Risk factors for recurrence of epilepsy and withdrawal of antiepileptic therapy: a practical approach. Ann Med. 2003;35:207-215.
46. Silanpaa M, Schmidt D. Prognosis of seizure recurrence after stopping antiepileptic drugs in seizure-free patients: a long-term population-based study of childhood-onset epilepsy. Epilepsy Beh. 2006;8:713-719.
47. Peters ACB, Brouwer OF, Geerts AT, et al. Randomized prospective study of early discontinuation of antiepileptic drugs in children with epilepsy. Neurology. 1998;50:724-730.
48. Tennison M, Greenwood R, Lewis D, et al. Discontinuing antiepileptic drugs in children with epilepsy. A comparison of a six-week and a nine-month taper period. N Engl J Med. 1994;330:1407-1410.
49. Geerts A, Niermeijer J, Peters A, et al. Four-year outcome after early withdrawal of antiepileptic drugs in childhood epilepsy. Neurology. 2005;64: 2136-2138.
50. Sirven JI, Sperling M, Wingerchuk DM. Early versus late antiepileptic drug withdrawal for people with epilepsy in remission. Cochrane Database Syst Rev. 2001;3.
51. Andersson T, Braathen G, Persson A, et al. A comparison between one and three years of treatment in uncomplicated childhood epilepsy: a prospective study. II. The EEG as predictor of outcome after withdrawal of treatment. Epilepsia. 1997;38:225-232.
52. Verrotti A, Morresi S, Basciani F, et al. Discontinuation of anticonvulsant therapy in children with partial epilepsy. Neurology. 2000;55:1393-1395.
53. Chadwick D, Taylor J, Johnson T. Outcomes after seizure recurrence in people with well-controlled epilepsy and the factors that influence it. The MRC Antiepileptic Drug Withdrawal Group. Epilepsia. 1996;37:1043-1050.
54. Ohta H, Ohtsuka Y, Tsuda T, et al. Prognosis after withdrawal of antiepileptic drugs in childhood-onset cryptogenic localization-related epilepsies. Brain Dev. 2004;26:19-25.
55. Steinhoff BJ, Ueberall MA, Siemes H, LAM-SAFE Study Group. The LAM-SAFE Study: lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure. 2005;14:597-605.
56. Ben-Menachen E. Weight issues for people with epilepsy. Epilepsia. 2007; 48(suppl 9):42-45 [review].
57. Salinsky MC, Oken BS, Binder LM. Assessment of drowsiness in epilepsy patients receiving chronic antiepileptic drug therapy. Epilepsia. 1996;37:181-187.
58. Hessen E, Lossius MI, Reinvang I, et al. Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy. Epilepsia. 2006;47: 2038-2045.
59. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48:1223-1244 [review].